Nexien BioPharma, Inc. (NXEN)
Nexien BioPharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Glendale, CO, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $7,077. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of 0.0%. Its beta of -0.83 implies it has historically moved less than the broad market.
Nexien BioPharma, Inc., a pharmaceutical firm headquartered in Glendale, Colorado, concentrates its efforts on the research, advancement, and market introduction of cannabinoid-derived medications. The company utilizes both pre-clinical and clinical development paths to address a variety of diseases, medical conditions, and disorders. It adopted its current name in September 2018, having previously operated as Intiva BioPharma Inc.
Nexien BioPharma, Inc. is most often compared with the following Healthcare names: